All Relations between Muscle Weakness and dmd

Publication Sentence Publish Date Extraction Date Species
Patricia Piñol-Jurado, Xavier Suárez-Calvet, Esther Fernández-Simón, Eduard Gallardo, Natalia de la Oliva, Anna Martínez-Muriana, Pedro Gómez-Gálvez, Luis M Escudero, María Pérez-Peiró, Lutz Wollin, Noemi de Luna, Xavier Navarro, Isabel Illa, Jordi Díaz-Maner. Nintedanib decreases muscle fibrosis and improves muscle function in a murine model of dystrophinopathy. Cell death & disease. vol 9. issue 7. 2019-11-25. PMID:29991677. duchenne muscle dystrophy (dmd) is a genetic disorder characterized by progressive skeletal muscle weakness. 2019-11-25 2023-08-13 mouse
Kristin N Heller, Joshua T Mendell, Jerry R Mendell, Louise R Rodino-Klapa. MicroRNA-29 overexpression by adeno-associated virus suppresses fibrosis and restores muscle function in combination with micro-dystrophin. JCI insight. vol 2. issue 9. 2019-11-20. PMID:28469083. duchenne muscular dystrophy (dmd) is caused by dystrophin deficiency resulting in progressive muscle weakness and fibrotic scarring. 2019-11-20 2023-08-13 mouse
Megan A Waldrop, Felecia Gumienny, Saleh El Husayni, Diane E Frank, Robert B Weiss, Kevin M Flaniga. Low-level dystrophin expression attenuating the dystrophinopathy phenotype. Neuromuscular disorders : NMD. vol 28. issue 2. 2019-11-14. PMID:29305136. this case suggests that very low levels of dmd exon skipping and dystrophin protein expression may result in amelioration of skeletal muscle weakness, a finding relevant to current dystrophin-restoring therapies. 2019-11-14 2023-08-13 Not clear
Jana Strakova, Forum Kamdar, Debra Kulhanek, Maria Razzoli, Daniel J Garry, James M Ervasti, Alessandro Bartolomucci, DeWayne Townsen. Integrative effects of dystrophin loss on metabolic function of the mdx mouse. Scientific reports. vol 8. issue 1. 2019-10-28. PMID:30206270. duchenne muscular dystrophy (dmd) is a disease marked by the development of skeletal muscle weakness and wasting. 2019-10-28 2023-08-13 mouse
Lisa C Power, Gina L O'Grady, Tim S Hornung, Craig Jefferies, Silmara Gusso, Paul L Hofma. Imaging the heart to detect cardiomyopathy in Duchenne muscular dystrophy: A review. Neuromuscular disorders : NMD. vol 28. issue 9. 2019-10-25. PMID:30119965. mutations in the dmd gene on the x-chromosome result in progressive skeletal muscle weakness as the main clinical manifestation. 2019-10-25 2023-08-13 Not clear
Patrick Magrath, Nyasha Maforo, Pierangelo Renella, Stanley F Nelson, Nancy Halnon, Daniel B Enni. Cardiac MRI biomarkers for Duchenne muscular dystrophy. Biomarkers in medicine. vol 12. issue 11. 2019-09-05. PMID:30499689. duchenne muscular dystrophy (dmd) is a fatal inherited genetic disorder that results in progressive muscle weakness and ultimately loss of ambulation, respiratory failure and heart failure. 2019-09-05 2023-08-13 Not clear
Viktoriia Kyrychenko, Sergii Kyrychenko, Malte Tiburcy, John M Shelton, Chengzu Long, Jay W Schneider, Wolfram-Hubertus Zimmermann, Rhonda Bassel-Duby, Eric N Olso. Functional correction of dystrophin actin binding domain mutations by genome editing. JCI insight. vol 2. issue 18. 2019-08-26. PMID:28931764. duchenne muscular dystrophy (dmd) is caused by mutations in the dystrophin gene (dmd) that result in progressive, debilitating muscle weakness, cardiomyopathy, and a shortened lifespan. 2019-08-26 2023-08-13 human
Corinne A Betts, Graham McClorey, Richard Healicon, Suzan M Hammond, Raquel Manzano, Sofia Muses, Vicky Ball, Caroline Godfrey, Thomas M Merritt, Tirsa van Westering, Liz O'Donovan, Kim E Wells, Michael J Gait, Dominic J Wells, Damian Tyler, Matthew J Woo. Cmah-dystrophin deficient mdx mice display an accelerated cardiac phenotype that is improved following peptide-PMO exon skipping treatment. Human molecular genetics. vol 28. issue 3. 2019-07-15. PMID:30281092. duchenne muscular dystrophy (dmd) is caused by loss of dystrophin protein, leading to progressive muscle weakness and premature death due to respiratory and/or cardiac complications. 2019-07-15 2023-08-13 mouse
David R Weber, Stasia Hadjiyannakis, Hugh J McMillan, Garey Noritz, Leanne M War. Obesity and Endocrine Management of the Patient With Duchenne Muscular Dystrophy. Pediatrics. vol 142. issue Suppl 2. 2019-06-03. PMID:30275248. duchenne muscular dystrophy (dmd) is associated with an increased risk of endocrine complications due to the effects of prolonged glucocorticoid therapy as well as progressive muscle weakness. 2019-06-03 2023-08-13 Not clear
Mutsuki Kuraoka, Yuko Nitahara-Kasahara, Hisateru Tachimori, Naohiro Kato, Hiroyuki Shibasaki, Akihiko Shin, Yoshitsugu Aoki, En Kimura, Shin'ichi Taked. Accelerometric outcomes of motor function related to clinical evaluations and muscle involvement in dystrophic dogs. PloS one. vol 13. issue 12. 2019-05-30. PMID:30533017. patients with dmd reveal progressive muscle weakness leading to ambulatory dysfunction. 2019-05-30 2023-08-13 human
Jennifer G Andrews, Kristin Conway, Christina Westfield, Christina Trout, F John Meaney, Katherine Mathews, Emma Ciafaloni, Christopher Cunniff, Deborah J Fox, Dennis Matthews, Shree Pandy. Implementation of Duchenne Muscular Dystrophy Care Considerations. Pediatrics. vol 142. issue 1. 2019-04-29. PMID:29925575. duchenne muscular dystrophy (dmd) is an x-linked disorder characterized by progressive muscle weakness and multisystem involvement. 2019-04-29 2023-08-13 Not clear
Jennifer G Andrews, Molly M Lamb, Kristin Conway, Natalie Street, Christina Westfield, Emma Ciafaloni, Dennis Matthews, Christopher Cunniff, Shree Pandya, Deborah J Fo. Diagnostic Accuracy of Phenotype Classification in Duchenne and Becker Muscular Dystrophy Using Medical Record Data1. Journal of neuromuscular diseases. vol 5. issue 4. 2019-01-31. PMID:30320597. dystrophinopathies are caused by mutations in dmd resulting in progressive muscle weakness. 2019-01-31 2023-08-13 Not clear
Marianna Laviola, Rita Priori, Maria Grazia D'Angelo, Andrea Alivert. Assessment of diaphragmatic thickness by ultrasonography in Duchenne muscular dystrophy (DMD) patients. PloS one. vol 13. issue 7. 2019-01-30. PMID:30048455. in duchenne muscular dystrophy (dmd) the assessment of diaphragmatic function is crucial because respiratory muscle weakness can cause respiratory failure. 2019-01-30 2023-08-13 Not clear
Sabrina Poonja, Alyssa Power, Jean K Mah, Nowell M Fine, Steven C Greenwa. Current Cardiac Imaging Approaches in Duchenne Muscular Dystrophy. Journal of clinical neuromuscular disease. vol 20. issue 2. 2019-01-29. PMID:30439754. duchenne muscular dystrophy (dmd) is an x-linked neuromuscular condition caused by mutations in the dystrophin gene leading to skeletal muscle weakness and dilated cardiomyopathy. 2019-01-29 2023-08-13 Not clear
Wen-Chen Liang, Chen-Hua Wang, Po-Ching Chou, Wan-Zi Chen, Yuh-Jyh Jon. The natural history of the patients with Duchenne muscular dystrophy in Taiwan: A medical center experience. Pediatrics and neonatology. vol 59. issue 2. 2019-01-07. PMID:28903883. in addition to progressive proximal muscle weakness, respiratory, orthopedic, and gastrointestinal complications are often observed in dmd. 2019-01-07 2023-08-13 Not clear
Kota Utsumi, Kouji Takano, Yoji Okahara, Tetsuo Komori, Osamu Onodera, Kenji Kansak. Operation of a P300-based brain-computer interface in patients with Duchenne muscular dystrophy. Scientific reports. vol 8. issue 1. 2018-12-11. PMID:29379140. this technology has been tested in paralysed patients, such as those with cervical spinal cord injuries or amyotrophic lateral sclerosis, but it has not been tested systematically in duchenne muscular dystrophy (dmd), which is a severe type of muscular dystrophy due to the loss of dystrophin and is often accompanied by progressive muscle weakness and wasting. 2018-12-11 2023-08-13 Not clear
Marije Goudriaan, Marleen Van den Hauwe, Cristina Simon-Martinez, Catherine Huenaerts, Guy Molenaers, Nathalie Goemans, Kaat Desloover. Gait deviations in Duchenne muscular dystrophy-Part 2. Statistical non-parametric mapping to analyze gait deviations in children with Duchenne muscular dystrophy. Gait & posture. vol 63. 2018-10-24. PMID:29751322. also, while muscle weakness is often suggested to be the main cause for the altered gait pattern in dmd, this was never verified. 2018-10-24 2023-08-13 Not clear
Arash Salmaninejad, Saeed Farajzadeh Valilou, Hadi Bayat, Nader Ebadi, Abdolreza Daraei, Meysam Yousefi, Abolfazl Nesaei, Majid Mojarra. Duchenne muscular dystrophy: an updated review of common available therapies. The International journal of neuroscience. vol 128. issue 9. 2018-10-11. PMID:29351004. dmd leads to progressive muscle weakness, degeneration, and wasting; finally, follows with the premature demise in affected individuals due to respiratory and/or cardiac failure typically by age of 30. 2018-10-11 2023-08-13 Not clear
Michael St Andre, Mark Johnson, Prashant N Bansal, Jeremy Wellen, Andrew Robertson, Alan Opsahl, Peter M Burch, Peter Bialek, Carl Morris, Jane Owen. A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys. Skeletal muscle. vol 7. issue 1. 2018-09-24. PMID:29121992. therefore, myostatin blockade via a specific antibody could ameliorate the muscle weakness in dmd patients by increasing skeletal muscle mass and function, thereby reducing patients' functional decline. 2018-09-24 2023-08-13 mouse
Antonio Filareto, Katie Maguire-Nguyen, Qiang Gan, Garazi Aldanondo, Léo Machado, Jeffrey S Chamberlain, Thomas A Rand. Monitoring disease activity noninvasively in the Proceedings of the National Academy of Sciences of the United States of America. vol 115. issue 30. 2018-09-17. PMID:29987034. dmd is characterized by progressive loss of muscle fibers, muscle weakness, and eventually loss of ambulation and premature death. 2018-09-17 2023-08-13 Not clear